Compare · AZN vs CDT
AZN vs CDT
Side-by-side comparison of AstraZeneca PLC (AZN) and CDT Equity Inc. (CDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and CDT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $285.36B, about 737042.9x CDT ($387,175).
- AZN has been more active in the news (22 items in the past 4 weeks vs 15 for CDT).
- AZN has more recent analyst coverage (25 ratings vs 0 for CDT).
- Company
- AstraZeneca PLC
- CDT Equity Inc.
- Price
- -
- -
- Market cap
- $285.36B
- $387,175
- 1M return
- +11.24%
- -
- 1Y return
- +105.93%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2022
- News (4w)
- 22
- 15
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- SEC Form 6-K filed by AstraZeneca PLC
Latest CDT
- CDT Equity Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo
- SEC Form 424B3 filed by CDT Equity Inc.
- CDT Equity Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form SCHEDULE 13D/A filed by CDT Equity Inc.
- SEC Form 424B3 filed by CDT Equity Inc.
- CDT Equity Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 424B3 filed by CDT Equity Inc.
- CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
- SEC Form DEF 14A filed by CDT Equity Inc.